HIV associated nephropathy future or investigational therapies

HIV associated nephropathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating HIV associated nephropathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
KUB X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
HIV associated nephropathy future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of HIV associated nephropathy future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on HIV associated nephropathy future or investigational therapies
CDC on HIV associated nephropathy future or investigational therapies
HIV associated nephropathy future or investigational therapies in the news
Blogs on HIV associated nephropathy future or investigational therapies
Directions to Hospitals Treating HIV associated nephropathy
Risk calculators and risk factors for HIV associated nephropathy future or investigational therapies

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Future or Investigational Therapies

• more research is needed to determine novel therapies such as molecular targeting to prevent or delay progression to ESRD. 
• The initiation of HIV-positive donor to HIV-positive recipient kidney transplantation, in South Africa and now available in the United States, offers great promise to patients who previously may not have survived to transplantation, though long-term outcomes remain unclear as well as the lack of data on estimated risk of recurrent disease.